|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-10-25
|
|
pubmed:abstractText |
Atherogenic dyslipidemia is emerging as a target of lipid-modifying therapy. However, an optimal pharmacologic approach has not yet been established. The aim of this study is to compare the efficacy and tolerability of the typical doses of fenofibrate and niacin.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1879-1484
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
213
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
235-40
|
|
pubmed:meshHeading |
pubmed-meshheading:20855072-Adult,
pubmed-meshheading:20855072-Aged,
pubmed-meshheading:20855072-Apolipoprotein A-I,
pubmed-meshheading:20855072-Apolipoproteins B,
pubmed-meshheading:20855072-Cholesterol, HDL,
pubmed-meshheading:20855072-Female,
pubmed-meshheading:20855072-Fenofibrate,
pubmed-meshheading:20855072-Fibric Acids,
pubmed-meshheading:20855072-Glucose,
pubmed-meshheading:20855072-Humans,
pubmed-meshheading:20855072-Hypertriglyceridemia,
pubmed-meshheading:20855072-Hypolipidemic Agents,
pubmed-meshheading:20855072-Inflammation,
pubmed-meshheading:20855072-Male,
pubmed-meshheading:20855072-Middle Aged,
pubmed-meshheading:20855072-Niacin
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.
|
|
pubmed:affiliation |
Cardiology Division, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
